Based on an analysis done by the European Medicines Agency on the feasibility of alternatives, the European Commission ...

Dave Miller, PhD, explains how environmental audits, waste reduction, and supply chain security are reshaping priorities in pharmaceutical manufacturing.

Dave Miller, PhD, discusses how shifting drug manufacturing to domestic CDMOs can improve quality, reduce rework, and enhance ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

Florida’s emergency rule will classify certain concentration forms of 7-hydroxymitragynine opioid products as Schedule 1 controlled substances in Florida, a step FDA recommended for 7-OH opioids in ...

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

The company’s expanded label for Avtozma (tocilizumab-anoh) now includes the treatment of cytokine release syndrome, aligning ...

The scaled adoption of cell and gene therapies demands a new era of agile, precise, and efficient quality control methods.

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Experts from LGM Pharma and Rockwell Automation share their thoughts on what makes tech transfer effective, where processes ...

The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...